Osteoclast-derived small extracellular vesicle as novel liquid biopsy for assessing bone health in older adults

Abstract Age-related bone loss is a highly prevalent condition that contributes substantially to morbidity, mortality, and healthcare costs worldwide. Dysregulated osteoclast activity characterizes aging bone; however, current diagnostic measurements lack specificity, sensitivity, and early detection ability. Small extracellular vesicles (sEV) derived from specific cell types offer a promising non-invasive liquid biopsy approach for assessing hard-to-access tissues, like bone. This proof-of-concept study aimed to isolate osteoclast-specific sEV (sEV-Osteoclast) from blood, laying the foundation for a sensitive, specific, and repeatable method to evaluate osteoclast physiology and molecular status of bone in clinical studies. Four osteoclast-specific surface markers (tartrate-resistant acid phosphatase (TRAP), receptor activator of nuclear factor kappa-Β (RANK), integrin alpha V (CD51) and dendritic cell-specific transmembrane protein (DCStamp)) were identified through extensive literature review and validated using the Human Protein Atlas and UniProt databases. Next, total sEV were isolated from human plasma samples (n = 11; age: 70.0±2.76 years) and characterized for size (99.65±2.49nm) and concentration (3.58E+11±3.13E+10particle/ml) by nanoparticle tracking analysis. Next, the percentage of sEVOsteoclast markers in the total sEV was ascertained by flow cytometry, revealing that 6.70±0.80% of plasma-total sEV were TRAP positive (+), 2.54±0.27% were RANK+, 7.36±0.64% were CD51+, and 3.63±0.27% were DCStamp+. As any specific sEV population can be reliably isolated from plasma if the percentage positivity is ≥ 2% in total sEV, these preliminary findings demonstrate feasibility of sEV-Osteoclast isolation from plasma. Future work aims to measure sEV-Osteoclast in a NIA-funded clinical trial of weight loss in older adults (NCT05764733), as a biomarker of early risk assessment and real-time intervention monitoring.

Authors

Institutions

Publication Details

Journal
Innovation in Aging
Published
2025-12-01
DOI
https://doi.org/10.1093/geroni/igaf122.4167
Primary Topic
Extracellular vesicles in disease
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Osteoclast-derived small extracellular vesicle as novel liquid biopsy for assessing bone health in older adults

Kristen M. Beavers, Sidharth P. Mishra, Ashish Kumar, Gagan Deep et al.
Innovation in Aging
Extracellular vesicles in disease
article

Osteoclast-derived small extracellular vesicle as novel liquid biopsy for assessing bone health in older adults

Kristen M. Beavers, Sidharth P. Mishra, Ashish Kumar, Gagan Deep, Yixin Su, Sangeeta Singh
article en

Abstract

Abstract Age-related bone loss is a highly prevalent condition that contributes substantially to morbidity, mortality, and healthcare costs worldwide. Dysregulated osteoclast activity characterizes aging bone; however, current diagnostic measurements lack specificity, sensitivity, and early detection ability. Small extracellular vesicles (sEV) derived from specific cell types offer a promising non-invasive liquid biopsy approach for assessing hard-to-access tissues, like bone. This proof-of-concept study aimed to isolate osteoclast-specific sEV (sEV-Osteoclast) from blood, laying the foundation for a sensitive, specific, and repeatable method to evaluate osteoclast physiology and molecular status of bone in clinical studies. Four osteoclast-specific surface markers (tartrate-resistant acid phosphatase (TRAP), receptor activator of nuclear factor kappa-Β (RANK), integrin alpha V (CD51) and dendritic cell-specific transmembrane protein (DCStamp)) were identified through extensive literature review and validated using the Human Protein Atlas and UniProt databases. Next, total sEV were isolated from human plasma samples (n = 11; age: 70.0±2.76 years) and characterized for size (99.65±2.49nm) and concentration (3.58E+11±3.13E+10particle/ml) by nanoparticle tracking analysis. Next, the percentage of sEVOsteoclast markers in the total sEV was ascertained by flow cytometry, revealing that 6.70±0.80% of plasma-total sEV were TRAP positive (+), 2.54±0.27% were RANK+, 7.36±0.64% were CD51+, and 3.63±0.27% were DCStamp+. As any specific sEV population can be reliably isolated from plasma if the percentage positivity is ≥ 2% in total sEV, these preliminary findings demonstrate feasibility of sEV-Osteoclast isolation from plasma. Future work aims to measure sEV-Osteoclast in a NIA-funded clinical trial of weight loss in older adults (NCT05764733), as a biomarker of early risk assessment and real-time intervention monitoring.

Innovation in AgingVol. 9(Supplement_2)
Wake Forest University (US)
Good health and well-being
Openalex Percentile: Top 35%
Extracellular vesicles in disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.